非布司他的用法及用量

It is a xanthine oxidase (XO) inhibitor suitable for the chronic management of hyperuricemic gout patients. Gout occurs due to excessive production of uric acid in the body and reduced kidney clearance ability. Uric acid accumulates in the body, leading to the deposition of urate crystals in joints and various organs. Therefore, the usual treatment for gout is to promote uric acid excretion and inhibit uric acid production, and take appropriate measures to improve related symptoms. The production of uric acid in the body is related to purine metabolism. In the final step of purine metabolism, hypoxanthine generates xanthine under the action of xanthine oxidoreductase (XOR), and then further generates uric acid. Inhibiting the activity of this enzyme can effectively reduce the production of uric acid. Febuxostat is the latest XOR inhibitor developed in the world. It acts highly selectively on this oxidase to reduce the synthesis of uric acid in the body and lower the concentration of uric acid, thereby effectively treating gout. 

Febuxostat is a potent non-purine selective inhibitor of xanthine oxidase (XO). By selectively inhibiting xanthine oxidase, it can achieve the therapeutic effect of reducing serum uric acid. Uric acid is the end product of purine metabolism and is produced in the cascade reaction of hypoxanthine → xanthine → uric acid. Each step of the conversion is catalyzed by xanthine oxidase. Febuxostat has been shown to effectively inhibit both the oxidized and reduced forms of xanthine oxidase. Febuxostat at therapeutic concentrations does not inhibit other enzymes involved in purine or pyrimidine metabolism, namely guanine deaminase, hypoxanthine guanine phosphoribosyltransferase, orotate phosphoribosyltransferase, orotate monophosphate decarboxylase, or purine nucleoside phosphorylase. 

The recommended oral dose of febuxostat tablets is 40 mg or 80 mg once daily. The recommended starting dose of febuxostat tablets is 40 mg once daily. If the blood uric acid level is still not less than 6 mg/dl (approximately 360 µmol/L) after 2 weeks, it is recommended that the dose be increased to 80 mg once a day. Food and antacid effects do not need to be considered when administering the drug. Special groups such as patients with hepatic insufficiency: Patients with mild or moderate hepatic insufficiency (Child-Pugh A, B) do not need to adjust the dose. The efficacy and safety of febuxostat in patients with severe hepatic insufficiency (Child-Pugh class C) have not been studied and should be used with caution in these patients.